May 03, 2022
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
Apr 18, 2022
ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE
Apr 07, 2022
Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited
Apr 04, 2022
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction
Mar 10, 2022
Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
Mar 03, 2022
Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit
Feb 24, 2022
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
Feb 24, 2022
Oncotelic Presenting at BiotechGate Digital Partnering
Jan 19, 2022
Oncotelic Presenting at BiotechGate Digital Partnering
Jan 05, 2022
Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma
1
2
3
4
5
6
7
8
9
10
<<
<
>
>>
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
Privacy